- Home
- FORA vs TENX Comparison
FORA vs TENX Comparison
Compare FORA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | TENX |
|---|---|---|
| Founded | 2014 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 56.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FORA | TENX |
|---|---|---|
| Price | $2.13 | $12.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 30.1K | ★ 200.9K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,106,911.00 | N/A |
| Revenue This Year | $47.82 | N/A |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | N/A |
| 52 Week Low | $1.64 | $4.63 |
| 52 Week High | $4.03 | $14.22 |
Technical Indicators
Market Signals| Indicator | FORA | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 60.93 |
| Support Level | $2.06 | $11.06 |
| Resistance Level | $2.12 | $13.00 |
| Average True Range (ATR) | 0.05 | 1.15 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 64.33 | 48.47 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.